CRUS
Cirrus Logic, Inc.
CRUS trails on the overall score without a compensating advantage in the available component scores.
MU
Micron Technology, Inc.
MU has the edge over CRUS overall, supported by stronger modeled upside and stronger valuation.
CRUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
CRUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
CRUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 15x | $122 | — |
| Cheap | 16x | $128 | +4.8% |
| Fair | 21x | $168 | +38% |
| Expensive | 28x | $219 | +80% |
Historical ranges are pointers, not guarantees.
CRUS has the edge over MU in the historical PE scenario, which offers more potential upside but is not a forecast.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU's PE is in its cheap range at 11x. If earnings grow as analysts expect, today's price would be 4.6x next year's earnings.
CRUS Forward outlook
There aren't enough analyst estimates for CRUS to show an outlook.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for MU, with profitability improving.
CRUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $7.93 | +13% |
| Q2 2026 | $8.18 | +28% |
| Q1 2026 | $7.85 | +31% |
| Q4 2025 | $7.58 | +38% |
| Q3 2025 | $7.03 | +20% |
| Q2 2025 | $6.38 | +19% |
| Q1 2025 | $6.00 | +22% |
| Q4 2024 | $5.48 | +73% |
CRUS's earnings per share have climbed steadily: $7.93 over the past year, up 13% from the year before, and higher year over year for 11 quarters in a row.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU's earnings per share have climbed steadily: $74.33 over the past year, about 10 times what it earned the year before, and higher year over year for 10 quarters in a row.
CRUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $559.5M | -0.3% |
| Q2 2026 | $459.7M | +13% |
| Q1 2026 | $448.5M | +5.7% |
| Q4 2025 | $580.6M | +4.5% |
| Q3 2025 | $561M | +3.5% |
| Q2 2025 | $407.3M | +8.9% |
| Q1 2025 | $424.5M | +14% |
| Q4 2024 | $555.7M | -10% |
CRUS's revenue is growing: $559M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -2.1 points |
| Q2 2026 | 18% | +0.6 points |
| Q1 2026 | 20% | -0.1 points |
| Q4 2025 | 26% | +0.1 points |
| Q3 2025 | 26% | +1.5 points |
| Q2 2025 | 18% | +5.3 points |
| Q1 2025 | 20% | +6.2 points |
| Q4 2024 | 26% | -0.8 points |
CRUS's operating margin was 24% last quarter, down 2.1 points from the same quarter a year ago.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU has the edge over CRUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU has the edge over CRUS on profitability, with a higher operating margin.
CRUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $42.5M | -52% |
| Q2 2026 | $49M | -57% |
| Q1 2026 | $149M | +17% |
| Q4 2025 | $285.7M | +35% |
| Q3 2025 | $88.3M | +1489% |
| Q2 2025 | $113.5M | +47% |
| Q1 2025 | $127M | -22% |
| Q4 2024 | $211.9M | -30% |
CRUS generated $526M in free cash flow over the past year, down 2.7% from the year before.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU has the edge over CRUS on cash flow, with more consistent year-over-year improvement.
CRUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -872K shares |
| 1 year | -3% | -1.6M shares |
| 3 years | -8.5% | -4.8M shares |
| 5 years | -13% | -8M shares |
| Available history | -15% | -9M shares |
CRUS has the edge over MU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $128.5M |
| Q2 2026 | $31.5M |
| Q1 2026 | $70M |
| Q4 2025 | $70M |
| Q3 2025 | $40M |
| Q2 2025 | $100M |
| Q1 2025 | $100M |
| Q4 2024 | $70M |
CRUS spent $300M buying back its own shares over the past year, down 3.2% from the year before.
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has 1.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
CRUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | -1.6x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.2x | Net Cash |
CRUS has the edge over MU on leverage, with a lower net debt burden relative to earnings.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has more cash than debt.
CRUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 41.1 | Neutral |
CRUS's weekly RSI is 47 (neutral) and its Stochastic is 41 (neutral).
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
CRUS PE vs Technology Sector
| Metric | CRUS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 28x | 45% below |
| PE % | 15 | 35 | 20 pts below |
CRUS is trading at 15x earnings, a 45% discount to the Technology sector's median of 28x.
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU has the edge over CRUS on valuation relative to its sector.
CRUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $114.2 | 6.6% above |
| 20 week MA | $121.6 | 0.1% above |
| 50 week MA | $135.7 | 10% below |
| 100 week MA | $121.5 | 0.2% above |
| 200 week MA | $108.8 | 12% above |
CRUS has the edge over MU on trend strength, trading above more of its moving averages.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 225% above its 200-week average.
CRUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.4 | $81.0 | -2.9% |
| 2021 | $81.0 | $91.5 | +13% |
| 2022 | $91.5 | $75.0 | -18% |
| 2023 | $75.0 | $83.2 | +11% |
| 2024 | $83.2 | $101.9 | +22% |
| 2025 | $101.9 | $120.9 | +19% |
| 2026 YTD | $120.9 | $121.7 | +0.7% |
CRUS has finished higher in four of the last six years. It's up 0.7% so far in 2026.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over CRUS on returns for 2026, with the stronger performance.